Assertio Therapeutic ASRT 深 沪
等待开盘 10-29 09:30:00 美东时间
0.8129
+0.002
+0.20%
华盛通- 最 高0.82
- 今 开0.81
- 成交量 30.39万股
- 最 低 0.8014
- 昨 收 0.8113
- 总市值 7823.32万
- 52周最高 1.08
- 市盈率 静 --
- 换手率 0.32%
- 52周最低 0.5137
- 委 比 -98.87%
- 总股本 9623.96万
- 历史最高 26.26
- 量 比 2.12
- 振 幅 2.29%
- 历史最低 0.5137
- 每 手 1
- 风险率 0.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Assertio Appoints Mark L. Reisenauer As CEO, Effective Immediately, Succeeding Brendan P. O'Grady
Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), today announced that its Board of Directors (the "Board") has appointed director Mark L. Reisenauer as the Company's Chief Executive Officer ("CEO"),
10-28 21:16
Assertio Announces Leadership Transition
Assertio Holdings appointed Mark L. Reisenauer as CEO, effective immediately, succeeding Brendan P. O’Grady. Reisenauer, with over 30 years of experience in oncology and specialty products, is expected to lead the company's growth and efficiency. Assertio will report third-quarter 2025 results on November 10, 2025, and provide guidance updates. The company emphasized Reisenauer's expertise and stakeholder benefits from his leadership. A live webc...
10-28 13:15
Assertio Therapeutics Amends ROLVEDON Supply Agreement
Assertio Therapeutics ( ($ASRT) ) just unveiled an update. On October 7, 2025, ...
10-11 05:18
Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV
Assertio announced new real-world data on SYMPAZAN (clobazam) Oral Film in treating Lennox-Gastaut Syndrome (LGS), a severe childhood epilepsy. Presented at the 150th American Neurological Association meeting, the study highlights SYMPAZAN's use in clinical practice, particularly for patients with swallowing difficulties. SYMPAZAN is the only FDA-approved oral film formulation for LGS seizures in patients aged two and older. The study analyzed 18...
09-15 13:00
Assertio Holdings Will Present New Data For Sympazan (Clobazam) At The Annual Meeting Of The American Neurological Association
Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or
09-10 19:32
Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association
Assertio Holdings, Inc. announced it will present new data on SYMPAZAN (clobazam) Oral Film at the 150th American Neurological Association Annual Meeting. The presentation will include real-world evidence on patients with Lennox-Gastaut Syndrome. SYMPAZAN is the only FDA-approved oral film formulation for adjunctive seizure treatment in LGS. Important safety information and usage guidelines are provided, including risks of concomitant opioid use,...
09-10 11:30
Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025
Assertio Holdings, Inc. announced that its management team will host investor meetings at two conferences in New York City during September 2025. The first meeting will be at the HC Wainwright Conference on September 10, 2025, at the Lotte New York Palace Hotel, with registration through HC Wainwright representatives. The second meeting will be at the Lake Street Capital Markets BIG9 Conference on September 11, 2025, at the Yale Club New York Cit...
09-03 12:15
HC Wainwright & Co. Maintains Buy on Assertio Holdings, Lowers Price Target to $3
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Assertio Holdings (NASDAQ:ASRT) with a Buy and lowers the price target from $3.5 to $3.
08-12 20:08
Assertio narrows 2025 sales guidance to $108M–$118M as transformation accelerates
Earnings Call Insights: Assertio Holdings, Inc. (ASRT) Q2 2025 Management View CEO Brendan P. O’Grady highlighted that "second quarter net product sales came in on plan at $28.8 million." He emphasize...
08-12 07:42
Assertio Holdings rises on revenue, adjusted profit beat
Assertio Holdings (NASDAQ:ASRT) shares rose post market on Monday after it posted second quarter revenue and adjusted profit above estimates, helped by growth in demand for Rolvedon. The company repor...
08-12 04:56
